TABLE 2.
Univariate analysis | Multi‐variate analysis | |||||||
---|---|---|---|---|---|---|---|---|
B | SE | Wald | df | p | Exp (B) | p | Exp (B) | |
General parameters | ||||||||
Age | 0.013 | 0.006 | 4.454 | 1.000 | 0.035* | 1.013 | 0.021* | 1.020 |
BMI | −0.033 | 0.017 | 3.890 | 1.000 | 0.049* | 0.968 | 0.152 | 0.974 |
ECOG | −1.056 | 0.589 | 3.223 | 1.000 | 0.002** | 0.348 | 0.471 | |
ISUP Group | 0.154 | 0.055 | 7.787 | 1.000 | 0.005** | 1.166 | 0.001** | 1.223 |
DeNovo Mets | 0.172 | 0.143 | 1.434 | 1.000 | 0.231 | 1.187 | ||
1st ARAT agent | 0.278 | 0.117 | 5.619 | 1.000 | 0.018* | 1.321 | 0.386 | 1.128 |
Chemotherapy Naïve | −0.586 | 0.131 | 20.137 | 1.000 | < 0.0001** | 0.556 | < 0.0001** | 0.407 |
Duration from HSPC to CRPC | 0.000 | 0.000 | 1.300 | 1.000 | 0.254 | 1.000 | ||
Serum markers | ||||||||
iPSA | 0.000 | 0.000 | 0.725 | 1.000 | 0.395 | 1.000 | ||
Nadir PSA during ADT | 0.003 | 0.001 | 8.444 | 1.000 | 0.004** | 1.003 | 0.421 | 1.001 |
PSA when starting ARAT | 0.000 | 0.000 | 3.504 | 1.000 | 0.061 | 1.000 |
Abbreviations: ADT = androgen deprivation therapy; ARAT = androgen receptor‐axis‐targeted therapies; BMI = Body Mass Index; ECOG = Eastern Cooperative Oncology Group; ISUP = International Society of Urological Pathology; PSA = prostate‐specific antigen.
p < 0.05.
p < 0.01.